(Q39552767)

13 September 2017

Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients (English)

1 reference

13 September 2017

0 references

Flavia C Vasconcelos

1

1 reference

13 September 2017

Karina L Silva

2

1 reference

13 September 2017

Paloma Silva de Souza

3

1 reference

13 September 2017

Luiz Felipe R Silva

4

1 reference

13 September 2017

Arthur Moellmann-Coelho

5

1 reference

13 September 2017

Claudete E Klumb

6

1 reference

13 September 2017

Raquel Ciuvalschi Maia

7

1 reference

13 September 2017

2 December 2010

1 reference

Cytometry Part B: Clinical Cytometry

13 September 2017

1 reference

13 September 2017

80

1 reference

13 September 2017

3

1 reference

13 September 2017

158-166

1 reference

Molecular mechanisms of drug resistance in acute myeloid leukaemia

13 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

P-glycoprotein activity predicts outcome in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

Cells from chronic myelogenous leukaemia patients at presentation exhibit multidrug resistance not mediated by either MDR1 or MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

Functional consequence of MDR1 expression on imatinib intracellular concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

Imatinib is a substrate for various multidrug resistance proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

inferred from DOI database lookup

7 January 2021

based on heuristic

Studies of some mechanisms of drug resistance in chronic myeloid leukemia (CML)

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

inferred from DOI database lookup

7 January 2021

based on heuristic

Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20580

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CYTO.B.20580

1 reference

13 September 2017

1 reference